Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
NCT02689219Phase 2Terminated
- Start
- Mar 2016
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in non-seminomatous germ cell tumor (NSGCT). Started Mar 2016; status: terminated.
02
Drugs
brentuximab vedotin
03
Conditions
non-seminomatous germ cell tumor (NSGCT)
Beyond the preview
Go deeper on NCT02689219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02689219.